

December 2016

Novotech recognised as Asia Pacific growth leader by Frost & Sullivan research analysts

Sydney, Australia: Leading Asia Pacific CRO Novotech has won the *Clinical Research Organisation (CRO) Growth Excellence Leadership* award in Frost & Sullivan's Best Practice Awards for 2016.

In recognising Novotech for the prestigious award, Frost & Sullivan's Asia Pacific Healthcare Practice Industry Manager Sanjeev Kumar said "Novotech was recognised as a top CRO in Australia and Asia Pacific for excellence in service provision to biopharma clients. The company has exhibited strong growth in a complex environment and now has a physical presence in 11 Asia Pacific countries. It continues to invest in cutting-edge technology, in order to provide a high quality integrated service to its clients... Novotech's unique focus as an Asia Pacific headquartered midsize CRO ideally complements the growing needs of the biotech community."



Recipients of the 2016 Frost & Sullivan Australia Excellence Awards were identified based on an in-depth research conducted by Frost & Sullivan's analysts. The award categories offered each year are carefully reviewed and evaluated to reflect the current market landscape and include new emerging trends.

Novotech Chief Operating Officer Dr John Moller said: "It is very satisfying to have our commitment to our clients and leadership in the Asia Pacific region recognised. Having our extensive regional footprint allows us to provide clients with immediate customer service and direct access to in-country experts. This allows us to accelerate trial activity and address any country-specific questions as quickly as possible. We look forward to continuing to provide our clients with access to the wealth of clinical trial benefits available in the Asia Pacific region."



Novotech COO Dr John Moller

-ends -

About Novotech - www.novotech-cro.com

Established in 1996 and headquartered in Sydney, Novotech has a strong presence in the Asia Pacific region, running clinical trials in all key regional markets including Australia, New Zealand, China, Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia, Thailand and India.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and submissions, clinical monitoring, data management, statistical analysis, report write-up to ICH requirements, project management and vendor management.

Novotech also has worldwide reach through the company's network of strategic partners. Novotech - described by Frost & Sullivan as the best in its industry class for Australia-based CROs and recipient of the ARCS ANZ Clinical Trials award 'Best CRO'- brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area.



About the 2016 Frost & Sullivan Australia Excellence Awards

Founded in 2006, The Frost & Sullivan Excellence Awards is now in its 11th consecutive year and seeks to recognize companies and individuals that have pushed the boundaries of excellence - rising above the competition and demonstrating outstanding performance in the Australian market.

For more information about the Frost & Sullivan Excellence Awards, please visit <http://frost-apac.com/ausawards/>

For more information about Novotech's Clinical Research Organisation (CRO) Growth Excellence Leadership award from Frost & Sullivan, please visit <http://frost-apac.com/ausawards/popup/2016/novotech/>

Media contact for interviews:

Digital Mantra Group

Australia: +61 2 8006 0424 // USA: +1650 7985238

Email: team@dmgpr.com